tetano
Editor, Senior Moderator
Antimicrob Agents Chemother
. 2022 Dec 15;e0135322.
doi: 10.1128/aac.01353-22. Online ahead of print.
Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19
Elizabeth E Zumbrun[SUP] 1 [/SUP], Chengzi I Kaku[SUP] 2 [/SUP], Lukas Dillinger[SUP] 3 [/SUP], Samantha E Zak[SUP] 1 [/SUP], Ana I Kuehne[SUP] 1 [/SUP], Russel R Bakken[SUP] 1 [/SUP], Jeffrey W Koehler[SUP] 1 [/SUP], Korey L Delp[SUP] 1 [/SUP], Christopher P Stefan[SUP] 1 [/SUP], Raina Kumar[SUP] 1 [/SUP], Jeffrey R Kugelman[SUP] 1 [/SUP], Alicia M Moreau[SUP] 1 [/SUP], Xiankun Zeng[SUP] 1 [/SUP], John M Dye[SUP] 1 [/SUP], Andrew S Herbert[SUP] 1 [/SUP], Kristin Narayan[SUP] 3 [/SUP], Laura M Walker[SUP] 3 [/SUP]
Affiliations
Abstract
Adintrevimab is a human immunoglobulin G1 monoclonal antibody engineered to have broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and other SARS-like coronaviruses with pandemic potential. In both Syrian golden hamster and rhesus macaque models, prophylactic administration of a single dose of adintrevimab provided protection against SARS-CoV-2/WA1/2020 infection in a dose-dependent manner, as measured by significant reductions in lung viral load and virus-induced lung pathology, and by inhibition of viral replication in the upper and lower respiratory tract.
Keywords: ADG20; COVID-19; SARS-CoV-2; adintrevimab; animal model; monoclonal antibody; preclinical; prevention.
. 2022 Dec 15;e0135322.
doi: 10.1128/aac.01353-22. Online ahead of print.
Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19
Elizabeth E Zumbrun[SUP] 1 [/SUP], Chengzi I Kaku[SUP] 2 [/SUP], Lukas Dillinger[SUP] 3 [/SUP], Samantha E Zak[SUP] 1 [/SUP], Ana I Kuehne[SUP] 1 [/SUP], Russel R Bakken[SUP] 1 [/SUP], Jeffrey W Koehler[SUP] 1 [/SUP], Korey L Delp[SUP] 1 [/SUP], Christopher P Stefan[SUP] 1 [/SUP], Raina Kumar[SUP] 1 [/SUP], Jeffrey R Kugelman[SUP] 1 [/SUP], Alicia M Moreau[SUP] 1 [/SUP], Xiankun Zeng[SUP] 1 [/SUP], John M Dye[SUP] 1 [/SUP], Andrew S Herbert[SUP] 1 [/SUP], Kristin Narayan[SUP] 3 [/SUP], Laura M Walker[SUP] 3 [/SUP]
Affiliations
- PMID: 36519929
- DOI: 10.1128/aac.01353-22
Abstract
Adintrevimab is a human immunoglobulin G1 monoclonal antibody engineered to have broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and other SARS-like coronaviruses with pandemic potential. In both Syrian golden hamster and rhesus macaque models, prophylactic administration of a single dose of adintrevimab provided protection against SARS-CoV-2/WA1/2020 infection in a dose-dependent manner, as measured by significant reductions in lung viral load and virus-induced lung pathology, and by inhibition of viral replication in the upper and lower respiratory tract.
Keywords: ADG20; COVID-19; SARS-CoV-2; adintrevimab; animal model; monoclonal antibody; preclinical; prevention.